http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Hyeontaek Hwang ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Efficacy of lower dose Pirfenidone for idiopathic pulmonary fibrosis in real practice of Korea
( Hyeontaek Hwang ),( Jung-kyu Lee ),( Sun Mi Choi ),( Jun Yeun Cho ),( Yeon Joo Lee ),( Young-jae Cho ),( Ho Il Yoon ),( Jae Ho Lee ),( Choon-taek Lee ),( Young Whan Kim ),( Jong Sun Park ) 대한결핵 및 호흡기학회 2018 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.126 No.-
Introduction: Pirfenidone reduced the rate of disease progression in patients with idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the efficacy and adverse events of pirfenidone in real practice of Korea and whether the lower dose of pirfenidone is also effective in patients with IPF. Method: This study was a multi-center retrospective cohort study of patients with IPF involved 3 referral centers in Korea. Patients treated with pirfenidone between July 2012 and March 2018 were enrolled. Efficacy was analyzed according to the dose of pirfenidone using linear mixed effects model for annual rate of decline in forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO). Results: A total of 338 patients were analyzed. The mean duration of treatment was 16.1±9.0 months. About 20% of the patients received pirfenidone as a standard dose (1800mg) for more than 6 months (standard dose group). However, 80% had pirfenidone below 1200mg (non-standard dose group). The annual decline of predicted FVC was -5.34% [95% CI -6.56, -4.12] per year before treatment with pirfenidone, but -2.89% [95% CI -3.64, -2.14] per year after treatment. The annual decline of FVC and DLCO was significantly attenuated after pirfenidone treatment (p<0.001), these effect was similar in both standard and non-standard dose groups. Conclusion: Pirfenidone reduced the rate of decline of FVC and DLCO in Korean IPF patients. This effect persists even after continual lower dose of pirfenidone.
-
( Hyeontaek Hwang ),( Jung-kyu Lee ),( Sun Mi Choi ),( Yeon Joo Lee ),( Young-jae Cho ),( Ho Il Yoon ),( Jae Ho Lee ),( Choon-taek Lee ),( Young Whan Kim ),( Jong Sun Park ) 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.2
Background/Aims: Pirfenidone slows the progression of idiopathic pulmonary fibrosis (IPF). We investigated its efficacy and safety in terms of dose and disease severity in real-world patients with IPF. Methods: This multicenter retrospective cohort study investigated 338 patients treated with pirfenidone between July 2012 and March 2018. Demographics, pulmonary function, mortality, and pirfenidone-related adverse events were also investigat ed. Efficacy was analyzed according to pirfenidone dose and disease severity using linear mixed-effects models to assess the annual decline rate of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DL<sub>CO</sub>). Results: The mean %FVC<sub>predicted</sub> and %DLCO<sub>predicted</sub> values were 72.6% ± 13.1% and 61.4% ± 17.9%, respectively. The mean duration of pirfenidone treatment was 16.1 ± 9.0 months. In the standard dose (1,800 mg/day) group, the mean %FVC<sub>predicted</sub> was -6.56% (95% confidence interval [CI], -9.26 to -3.87) per year before, but -4.43% (95% CI, -5.87 to -3.00) per year after treatment with pirfenidone. In the non-standard lower dose group, the mean %FVC<sub>predicted</sub> was -4.96% (95% CI, -6.82 to -3.09) per year before, but -1.79% (95% CI, -2.75 to -0.83) per year after treatment with pirfenidone. The FVC decline rate was significantly reduced, regardless of the Gender-Age-Physiology (GAP) stage. Adverse events and mortality were similar across dose groups; however, they were more frequent in GAP stages II-III than in the stage I group. Conclusions: The effect of pirfenidone on reducing disease progression of IPF persisted even with a consistently lower dose of pirfenidone.
KCI연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
